KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) EPS (Basic): 2016-2024

Historic EPS (Basic) for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to -$0.38.

  • Amneal Pharmaceuticals' EPS (Basic) fell 73.67% to $0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.02, marking a year-over-year increase of 102.43%. This contributed to the annual value of -$0.38 for FY2024, which is 20.83% up from last year.
  • According to the latest figures from FY2024, Amneal Pharmaceuticals' EPS (Basic) is -$0.38, which was up 20.83% from -$0.48 recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' EPS (Basic) registered a high of $0.62 during FY2020, and its lowest value of -$0.86 during FY2022.
  • For the 3-year period, Amneal Pharmaceuticals' EPS (Basic) averaged around -$0.57, with its median value being -$0.48 (2023).
  • Its EPS (Basic) has fluctuated over the past 5 years, first skyrocketed by 122.63% in 2020, then plummeted by 1,328.57% in 2022.
  • Over the past 5 years, Amneal Pharmaceuticals' EPS (Basic) (Yearly) stood at $0.62 in 2020, then tumbled by 88.71% to $0.07 in 2021, then plummeted by 1,328.57% to -$0.86 in 2022, then spiked by 44.19% to -$0.48 in 2023, then grew by 20.83% to -$0.38 in 2024.